Clinical Trials · NCT02090114
RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrollment
- 112
- Start date
- Aug 2014
- Locations
- 2 sites, United States
- Primary endpoint
- Prostate Specific Antigen (PSA) Response to Bipolar Androgen Therapy (BAT)